Literature DB >> 30190341

Efficacy of venetoclax monotherapy in patients with relapsed, refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor therapy.

Toby A Eyre1, Harriet S Walter2, Sunil Iyengar3, George Follows4, Matthew Cross3, Christopher P Fox5, Andrew Hodson6, Josh Coats7, Santosh Narat8, Nick Morley6, Martin J S Dyer2, Graham P Collins9.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30190341      PMCID: PMC6355471          DOI: 10.3324/haematol.2018.198812

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  14 in total

1.  Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma.

Authors:  Matthew S Davids; Andrew W Roberts; John F Seymour; John M Pagel; Brad S Kahl; William G Wierda; Soham Puvvada; Thomas J Kipps; Mary Ann Anderson; Ahmed Hamed Salem; Martin Dunbar; Ming Zhu; Franklin Peale; Jeremy A Ross; Lori Gressick; Monali Desai; Su Young Kim; Maria Verdugo; Rod A Humerickhouse; Gary B Gordon; John F Gerecitano
Journal:  J Clin Oncol       Date:  2017-01-17       Impact factor: 44.544

2.  Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma.

Authors:  Constantine S Tam; Mary Ann Anderson; Christiane Pott; Rishu Agarwal; Sasanka Handunnetti; Rodney J Hicks; Kate Burbury; Gillian Turner; Juliana Di Iulio; Mathias Bressel; David Westerman; Stephen Lade; Martin Dreyling; Sarah-Jane Dawson; Mark A Dawson; John F Seymour; Andrew W Roberts
Journal:  N Engl J Med       Date:  2018-03-29       Impact factor: 91.245

3.  Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes.

Authors:  C Y Cheah; D Chihara; J E Romaguera; N H Fowler; J F Seymour; F B Hagemeister; R E Champlin; M L Wang
Journal:  Ann Oncol       Date:  2015-02-23       Impact factor: 32.976

4.  Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study.

Authors:  A Goy; S H Bernstein; B S Kahl; B Djulbegovic; M J Robertson; S de Vos; E Epner; A Krishnan; J P Leonard; S Lonial; S Nasta; O A O'Connor; H Shi; A L Boral; R I Fisher
Journal:  Ann Oncol       Date:  2008-12-12       Impact factor: 32.976

5.  Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group.

Authors:  Christian H Geisler; Arne Kolstad; Anna Laurell; Niels S Andersen; Lone B Pedersen; Mats Jerkeman; Mikael Eriksson; Marie Nordström; Eva Kimby; Anne Marie Boesen; Outi Kuittinen; Grete F Lauritzsen; Herman Nilsson-Ehle; Elisabeth Ralfkiaer; Måns Akerman; Mats Ehinger; Christer Sundström; Ruth Langholm; Jan Delabie; Marja-Liisa Karjalainen-Lindsberg; Peter Brown; Erkki Elonen
Journal:  Blood       Date:  2008-07-14       Impact factor: 22.113

6.  Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma.

Authors:  Georg Hess; Raoul Herbrecht; Jorge Romaguera; Gregor Verhoef; Michael Crump; Christian Gisselbrecht; Anna Laurell; Fritz Offner; Andrew Strahs; Anna Berkenblit; Orysia Hanushevsky; Jill Clancy; Becker Hewes; Laurence Moore; Bertrand Coiffier
Journal:  J Clin Oncol       Date:  2009-07-06       Impact factor: 44.544

7.  Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial.

Authors:  Michael Wang; Simon Rule; Pier Luigi Zinzani; Andre Goy; Olivier Casasnovas; Stephen D Smith; Gandhi Damaj; Jeanette Doorduijn; Thierry Lamy; Franck Morschhauser; Carlos Panizo; Bijal Shah; Andrew Davies; Richard Eek; Jehan Dupuis; Eric Jacobsen; Arnon P Kater; Steven Le Gouill; Lucie Oberic; Taduesz Robak; Todd Covey; Richa Dua; Ahmed Hamdy; Xin Huang; Raquel Izumi; Priti Patel; Wayne Rothbaum; J Greg Slatter; Wojciech Jurczak
Journal:  Lancet       Date:  2017-12-11       Impact factor: 79.321

8.  Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial.

Authors:  Jeffrey A Jones; Anthony R Mato; William G Wierda; Matthew S Davids; Michael Choi; Bruce D Cheson; Richard R Furman; Nicole Lamanna; Paul M Barr; Lang Zhou; Brenda Chyla; Ahmed Hamed Salem; Maria Verdugo; Rod A Humerickhouse; Jalaja Potluri; Steven Coutre; Jennifer Woyach; John C Byrd
Journal:  Lancet Oncol       Date:  2017-12-12       Impact factor: 41.316

9.  Postibrutinib outcomes in patients with mantle cell lymphoma.

Authors:  Peter Martin; Kami Maddocks; John P Leonard; Jia Ruan; Andre Goy; Nina Wagner-Johnston; Simon Rule; Ranjana Advani; David Iberri; Tycel Phillips; Stephen Spurgeon; Eliana Kozin; Katherine Noto; Zhengming Chen; Wojciech Jurczak; Rebecca Auer; Ewa Chmielowska; Stephan Stilgenbauer; Johannes Bloehdorn; Craig Portell; Michael E Williams; Martin Dreyling; Paul M Barr; Selina Chen-Kiang; Maurizio DiLiberto; Richard R Furman; Kristie A Blum
Journal:  Blood       Date:  2016-01-13       Impact factor: 22.113

10.  Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.

Authors:  Michael L Wang; Simon Rule; Peter Martin; Andre Goy; Rebecca Auer; Brad S Kahl; Wojciech Jurczak; Ranjana H Advani; Jorge E Romaguera; Michael E Williams; Jacqueline C Barrientos; Ewa Chmielowska; John Radford; Stephan Stilgenbauer; Martin Dreyling; Wieslaw Wiktor Jedrzejczak; Peter Johnson; Stephen E Spurgeon; Lei Li; Liang Zhang; Kate Newberry; Zhishuo Ou; Nancy Cheng; Bingliang Fang; Jesse McGreivy; Fong Clow; Joseph J Buggy; Betty Y Chang; Darrin M Beaupre; Lori A Kunkel; Kristie A Blum
Journal:  N Engl J Med       Date:  2013-06-19       Impact factor: 91.245

View more
  32 in total

Review 1.  Management of Older Adults with Mantle Cell Lymphoma.

Authors:  Jason T Romancik; Jonathon B Cohen
Journal:  Drugs Aging       Date:  2020-07       Impact factor: 3.923

Review 2.  Sequencing of Novel Therapies for Mantle Cell Lymphoma.

Authors:  Jason T Romancik; Jonathon B Cohen
Journal:  Curr Treat Options Oncol       Date:  2021-11-23

3.  Modulation of BCL-2 in Both T Cells and Tumor Cells to Enhance Chimeric Antigen Receptor T-cell Immunotherapy against Cancer.

Authors:  Yong Gu Lee; Puneeth Guruprasad; Guido Ghilardi; Raymone Pajarillo; Christopher Tor Sauter; Ruchi Patel; Hatcher J Ballard; Seok Jae Hong; Inkook Chun; Nicholas Yang; Kimberly V Amelsberg; Katherine D Cummins; Jakub Svoboda; Saar Gill; Elise A Chong; Khrystyna North; Sarah E Church; Joseph A Fraietta; Wan-Jung Chang; Simon F Lacey; Xueqing Maggie Lu; Yunlin Zhang; Kanupriya Whig; David C Schultz; Sara Cherry; James Gerson; Stephen J Schuster; Patrizia Porazzi; Marco Ruella
Journal:  Cancer Discov       Date:  2022-10-05       Impact factor: 38.272

Review 4.  Mantle Cell Lymphoma: the Role of Risk-Adapted Therapy and Treatment of Relapsed Disease.

Authors:  Meri Tarockoff; Teresita Gonzalez; Stanislav Ivanov; Jose Sandoval-Sus
Journal:  Curr Oncol Rep       Date:  2022-05-31       Impact factor: 5.945

5.  KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma.

Authors:  Michael Wang; Javier Munoz; Andre Goy; Frederick L Locke; Caron A Jacobson; Brian T Hill; John M Timmerman; Houston Holmes; Samantha Jaglowski; Ian W Flinn; Peter A McSweeney; David B Miklos; John M Pagel; Marie-Jose Kersten; Noel Milpied; Henry Fung; Max S Topp; Roch Houot; Amer Beitinjaneh; Weimin Peng; Lianqing Zheng; John M Rossi; Rajul K Jain; Arati V Rao; Patrick M Reagan
Journal:  N Engl J Med       Date:  2020-04-02       Impact factor: 91.245

6.  Dual dependence on BCL2 and MCL1 in T-cell prolymphocytic leukemia.

Authors:  Victoria M Smith; Oliver Lomas; Donna Constantine; Lianne Palmer; Anna H Schuh; David Bruce; Oksana Gonchar; Salvador Macip; Sandrine Jayne; Martin J S Dyer; Toby A Eyre
Journal:  Blood Adv       Date:  2020-02-11

7.  Potent efficacy of MCL-1 inhibitor-based therapies in preclinical models of mantle cell lymphoma.

Authors:  Michael A Dengler; Charis E Teh; Rachel Thijssen; Lahiru Gangoda; Ping Lan; Marco J Herold; Daniel H Gray; Gemma L Kelly; Andrew W Roberts; Jerry M Adams
Journal:  Oncogene       Date:  2019-11-26       Impact factor: 9.867

8.  Final Results of a Phase I/II Trial of the Combination Bendamustine and Rituximab With Temsirolimus (BeRT) in Relapsed Mantle Cell Lymphoma and Follicular Lymphoma.

Authors:  Georg Hess; Karola Wagner; Ulrich Keller; Paul La Rosee; Johannes Atta; Kai Hübel; Christian Lerchenmueller; Daniel Schoendube; Mathias Witzens-Harig; Christian Ruckes; Christoph Medler; Christina van Oordt; Wolfram Klapper; Matthias Theobald; Martin Dreyling
Journal:  Hemasphere       Date:  2020-06-08

9.  Treatment of Central Nervous System Relapse in Acute Promyelocytic Leukemia by Venetoclax: A Case Report.

Authors:  Xuzhao Zhang; Jinliang Chen; Weiqin Wang; Xian Li; Yanbin Tan; Xiaohong Zhang; Wenbin Qian
Journal:  Front Oncol       Date:  2021-07-05       Impact factor: 6.244

10.  Bruton's tyrosine kinase inhibition induces rewiring of proximal and distal B-cell receptor signaling in mice.

Authors:  Jasper Rip; Marjolein J W de Bruijn; Stefan F H Neys; Simar Pal Singh; Jonas Willar; Jennifer A C van Hulst; Rudi W Hendriks; Odilia B J Corneth
Journal:  Eur J Immunol       Date:  2021-08-16       Impact factor: 6.688

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.